Information Provided By:
Fly News Breaks for July 30, 2018
BLUE
Jul 30, 2018 | 09:00 EDT
Maxim analyst Jason McCarthy lowered his price target on Bluebird Bio to $163 after the company's announced capital raise, expecting about $630M in proceeds. The analyst also keeps his Hold rating, saying that while the accelerated EMA assessment on LentiGlobin could reduce the review period to 150 days from 210 days, the company has "only incremental catalysts" in the short term.